Clinical trials: Hepatic Tumor Resection
Hepatocellular Carcinoma (HCC)
NWRD06 DNA Plasmid for HCC After Curative Resection.
This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma…
- Trial name
- NCT07324304
- Testing
- NWRD06 administered by electroporation
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Neoplasms
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00264446
- Testing
- ADH300004
- Where
- United States
- Sponsor
- Adherex Technologies, Inc.
Hepatocarcinoma, Hepatic Metastasis
Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery
This study aims at assessing the feasibility of Probe-based Confocal Laser Endomicroscopy (pCLE) during laparoscopic hepatic masses resection for intra-operative characterisation of hepatic masses and surgical margins assessment.
- Conditions
- Hepatocarcinoma, Hepatic Metastasis, Hepatic Tumor
- Trial name
- PERSEE (NCT03718078)
- Testing
- Confocal Laser Endomicroscopy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Primary Hepatocellular Carcinoma
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA)…
- Trial name
- DC-TC (NCT01828762)
- Testing
- DC-TC+GM-CSF
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai AbelZeta Ltd.
Carcinoma, Hepatocellular
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are…
- Trial name
- IMbrave050 (NCT04102098)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 134 sites in United States, Australia and 24 more
- Volunteers
- 668 people
- Sponsor
- Hoffmann-La Roche
Hepato Cellular Carcinoma (HCC), Liver Resection
Retrospective Clinical Validation of HepatoPredict
HepatoPredict is an innovative prognostic tool to support hepatologists, hepatobiliary surgeons and multidisciplinary teams in deciding on the best therapeutical approach for a patient with Hepatocellular Carcinoma, the most…
- Conditions
- Hepato Cellular Carcinoma (HCC), Liver Resection, Liver Transplantation
- Trial name
- NCT06894524
- Volunteers
- 200 people
- Sponsor
- Ophiomics
Cancer, Liver Cancer
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Primary Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATHWAY (NCT00568308)
- Testing
- PI-88
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Progen Pharmaceuticals
Hepatocellular Carcinoma
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and efficacy of autologous memory lymphocyte therapy (NewishT) in patients with hepatocellular carcinoma at high risk of recurrence…
- Trial name
- NCT05352646
- Testing
- Autologous memory lymphocyte Injection (NewishT), low-dose group, Autologous memory lymphocyte Injection (NewishT), high-dose group
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Hepatocellular Carcinoma, Renal Cell Carcinoma
Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T lymphocytes which present a mixed T-NK phenotype and are endowed with a major histocompatibility complex-unrestricted antitumor activity.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Lung Cancer
- Trial name
- NCT01914263
- Testing
- cytokine induced killer cell
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Alliancells-PuRui Biocience Co., Ltd.
Cancer, Liver Cancer
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATRON (NCT01402908)
- Testing
- PI-88
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 520 people
- Sponsor
- Cellxpert Biotechnology Corp.
Carcinoma, Hepatocellular
Sorafenib for Residue Disease After Resection With Curative Intent
Radical hepatic resection represents one of the treatment options offering a prospect for cure with 5-year survival rates up to 50%.
- Trial name
- SECURE (NCT01751763)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Bayer
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Hepatocellular Carcinoma
Expanding Phase III Study of Tyroserleutide for Injection
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT03516448
- Testing
- Gan Fu Le Tablets, Tyroserleutide for injection
- Volunteers
- 352 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea
- Trial name
- NCT06620510
- Testing
- Immuncell-LC, No Interventions
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma, Liver Cancer
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation…
- Trial name
- CheckMate 9DX (NCT03383458)
- Testing
- Nivolumab
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 545 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Hepatocellular Carcinoma (HCC)
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative…
- Trial name
- NCT04639180
- Testing
- Camrelizumab, Rivoceranib (Apatinib)
- Where
- 6 sites in China
- Volunteers
- 687 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hemorrhage
PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection…
- Trial name
- NCT02204930
- Testing
- PeproStat
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Haemostatix Ltd
Carcinoma, Hepatocellular
PI-88 in Hepatocellular Carcinoma After Hepatectomy
The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
- Trial name
- NCT00247728
- Testing
- PI-88
- Where
- 6 sites in Taiwan
- Volunteers
- 172 people
- Sponsor
- Cellxpert Biotechnology Corp.